- Home
- MQY vs COLL Comparison
MQY vs COLL Comparison
Compare MQY & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- COLL
- Stock Information
- Founded
- MQY 1994
- COLL 2002
- Country
- MQY United States
- COLL United States
- Employees
- MQY N/A
- COLL N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- MQY Finance
- COLL Health Care
- Exchange
- MQY Nasdaq
- COLL Nasdaq
- Market Cap
- MQY 836.9M
- COLL 910.2M
- IPO Year
- MQY N/A
- COLL 2015
- Fundamental
- Price
- MQY $11.76
- COLL $30.00
- Analyst Decision
- MQY
- COLL Strong Buy
- Analyst Count
- MQY 0
- COLL 5
- Target Price
- MQY N/A
- COLL $43.60
- AVG Volume (30 Days)
- MQY 184.8K
- COLL 444.8K
- Earning Date
- MQY 01-01-0001
- COLL 05-08-2025
- Dividend Yield
- MQY 4.73%
- COLL N/A
- EPS Growth
- MQY N/A
- COLL 43.56
- EPS
- MQY N/A
- COLL 1.86
- Revenue
- MQY N/A
- COLL $631,449,000.00
- Revenue This Year
- MQY N/A
- COLL $20.00
- Revenue Next Year
- MQY N/A
- COLL $3.93
- P/E Ratio
- MQY N/A
- COLL $16.09
- Revenue Growth
- MQY N/A
- COLL 11.41
- 52 Week Low
- MQY $9.82
- COLL $27.28
- 52 Week High
- MQY $12.52
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- MQY 47.16
- COLL 51.96
- Support Level
- MQY $11.63
- COLL $29.01
- Resistance Level
- MQY $11.87
- COLL $30.53
- Average True Range (ATR)
- MQY 0.12
- COLL 0.89
- MACD
- MQY 0.01
- COLL 0.04
- Stochastic Oscillator
- MQY 54.26
- COLL 62.91
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.